Skip to main content

Xencor Inc 10-Q for FY2026 Q3

Xencor Inc (XNCR)

10-Q 2026-11-04 For: 2026-09-30
View Original
Added on November 04, 2026

About this 10-Q

Xencor Inc filed this 10-Q on November 4, 2026, covering the quarter ended September 30, 2026 (FY2026 Q3).

XmAb819’s selected 400 mcg/kg IV dose produced five confirmed partial responses among 11 efficacy-evaluable patients, a 45.5% confirmed objective response rate. The Alexion settlement provides $105.0 million and ends U.S. Ultomiris royalties. AI summary

Headline figures

Quarter ended September 30, 2026, as reported in this filing, compared with the same period a year earlier where the filing states it.

Revenue
$116.52M
up 454.9% from $21M a year earlier
Net income
$39.44M
compared with a net loss of $6.03M a year earlier
Diluted EPS
$0.50
compared with -$0.08 a year earlier